Delving into the Latest Updates on United Immunity Co. Ltd. with Synapse

概览

疾病领域	数量

肿瘤	3

排名前五的药物类型	数量

T细胞疗法	2
CAR-M	1

排名前五的靶点	数量

NY-ESO-1(肿瘤/睾丸抗原-1)	1
TLR(Toll样受体)	1

关联

9

项与 United Immunity Co. Ltd. 相关的药物

UI-201

靶点

NY-ESO-1

作用机制

NY-ESO-1抑制剂

在研机构

United Immunity Co. Ltd.初创企业

原研机构

United Immunity Co. Ltd.初创企业

在研适应症

滑膜肉瘤

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

UI-102

靶点

TLR

作用机制

TLR拮抗剂

在研机构

United Immunity Co. Ltd.初创企业

原研机构

United Immunity Co. Ltd.初创企业

在研适应症

肝细胞癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

CAR-M(United Immunity)

靶点-

作用机制-

在研机构

United Immunity Co. Ltd.初创企业

原研机构

United Immunity Co. Ltd.初创企业

在研适应症

实体瘤

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 United Immunity Co. Ltd. 相关的临床结果

登录后查看更多信息

0 项与 United Immunity Co. Ltd. 相关的专利（医药）

登录后查看更多信息

6

项与 United Immunity Co. Ltd. 相关的文献（医药）

2022-07-01·Journal of Controlled Release1区 · 医学

Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance

1区 · 医学

Review

作者: Akiyoshi, Kazunari ; Muraoka, Daisuke ; Harada, Naozumi ; Shiku, Hiroshi

In therapeutic cancer vaccines, vaccine antigens must be efficiently delivered to the antigen-presenting cells (dendritic cells and macrophages) located in the lymphoid organs (lymph nodes and spleen) at the appropriate time to induce a potent antitumor immune response. Nanoparticle-based delivery systems in cancer immunotherapy are of great interest in recent year. We have developed a novel cancer vaccine that can use self-assembled polysaccharide nanogel of cholesteryl group-modified pullulan (CHP) as an antigen delivery system for clinical cancer immunotherapy for the first time. Additionally, we recently proposed a novel technology that uses CHP nanogels to regulate the function of tumor-associated macrophages, leading to an improvement in the tumor microenvironment. When combined with other immunotherapies, macrophage function modulation using CHP nanogels demonstrated a potent inhibitory effect against cancers resistant to immune checkpoint inhibition therapies. In this review, we discuss the applications of our unique drug nanodelivery system for CHP nanogels.

2021-11-12·Neuro-Oncology

IMMU-08. NOVEL NANOPARTICLE-BASED DELIVERY OF H3.3K27M PEPTIDE TO TUMOR-ASSOCIATED MACROPHAGES ENHANCES THE TUMOR HOMING OF H3.3K27M-TCR TRANSDUCED T-CELLS IN HLA-A2/DR1 TRANSGENIC MICE WITH H3.3K27M+

作者: Yamamichi, Akane ; Akiyoshi, Kazunari ; Kakihara, Bunta ; Shiku, Hiroshi ; Diebold, David ; Chuntova, Polly ; Okada, Hideho ; Chen, Tiffany ; Harada, Naozumi

AbstractWe have identified a novel HLA-A*02:01-restricted CD8 T-cell epitope encompassing the H3.3K27M mutation and a corresponding high-affinity T-cell receptor (TCR) that recognizes the epitope. While the development of adoptive cell transfer therapy using TCR-transduced T-cells holds a promise, we still need to overcome multiple challenges, such as suboptimal T-cell trafficking and the immunosuppressive environment of malignant glioma. For example, tumor-associated macrophages (TAMs) mediate immunosuppression but do not function as effective antigen-presenting cells. We have developed a novel cholesteryl pullulan (CHP) nanogel as a highly biocompatible and efficient vaccine delivery system targeting TAMs. In this study, we investigated whether the CHP nanogel loaded with the H3.3K27M peptide would deliver the peptide to TAMs and convert TAMs to better antigen-presenting cells that enhance the anti- H3.3K27M+ glioma activity of the TCR-transduced T-cells. As a clinically relevant mouse model, we used HLA-A2/HLA-DR1-transgenic mice and generated a syngeneic glioma cell line that expresses H3.3K27M from their astrocytes. We also generated a retroviral vector encoding the H3.3K27M-specific TCR for transduction of mouse T cells. HLA-A2/HLA-DR1-transgenic mice bearing day 16 intracerebral H3.3K27M+ glioma received an intravenous administration of the CHP nanogel along with poly-ICLC, a Toll-like receptor 3 agonist. The mice then received an intravenous infusion of TCR-transduced or control, non-transduced T-cells on the following day. The triple combination regimen with the CHP, poly-ICLC and TCR-transduced T-cells significantly suppressed the tumor growth, associated with increased levels of T-cell infiltration into the tumors compared with the dual-therapy with poly-ICLC and TCR-T-cells without the CHP. Furthermore, TAMs isolated from CHP-treated mice showed evidence of CHP-uptake, abilities to stimulate proliferation of TCR-transduced T-cells, and higher levels of HLA.A2 expression. These results suggest that the antigen-loaded CHP nanogel can promote the local antigen-presentation to T-cells and represent a promising approach for improving the efficacy of adoptive T-cell therapy for gliomas.

2020-01-25·Drug Delivery System

Nanogel antigen DDS toward overcoming immune resistance of cancer

作者: Akiyoshi, Kazunari ; Muraoka, Daisuke ; Harada, Naozumi ; Shiku, Hiroshi

100 项与 United Immunity Co. Ltd. 相关的药物交易

登录后查看更多信息

100 项与 United Immunity Co. Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

临床前

临床2期

1

6

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

UI-201 ( NY-ESO-1 )	滑膜肉瘤更多	临床2期
UI-102 ( TLR )	肝细胞癌更多	临床前
CAR-M(United Immunity)	实体瘤更多	药物发现
UI-4 ( HLA-A 24 )	血液肿瘤更多	终止
UI-101 ( TLR7 x TLR8 )	实体瘤更多	终止